Progyny Stock Performance
| PGNY Stock | USD 20.91 0.55 2.70% |
On a scale of 0 to 100, Progyny holds a performance score of 17. The company holds a Beta of 0.75, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Progyny's returns are expected to increase less than the market. However, during the bear market, the loss of holding Progyny is expected to be smaller as well. Please check Progyny's potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether Progyny's historical price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Progyny are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Progyny showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.7 | Five Day Return 4.39 | Year To Date Return 17.94 | Ten Year Return 31.18 | All Time Return 31.18 |
1 | Acquisition by Peter Anevski of 209500 shares of Progyny at 14.4825 subject to Rule 16b-3 | 12/23/2024 |
2 | Acquisition by David Schlanger of 150000 shares of Progyny at 14.6822 subject to Rule 16b-3 | 12/26/2024 |
3 | Bullish Move David Schlanger Shows Confidence, Acquires 2.20M In Progyny Stock | 12/27/2024 |
4 | Insider Trading | 01/10/2025 |
5 | Progyny Appoints Healthcare Veteran Debra Morris to Board of Directors | 01/16/2025 |
6 | Breaking Down Progyny 4 Analysts Share Their Views - Benzinga | 02/11/2025 |
7 | What To Expect From Progynys Q4 Earnings | 02/26/2025 |
8 | Progyny Inc Q4 2024 Earnings EPS of 0.12 Beats Estimate, Revenue Surges to 298.4 Million | 02/27/2025 |
9 | Progyny Tops EPS Forecast, Eyes Growth | 02/28/2025 |
10 | Q4 Earnings Highlights UnitedHealth Vs The Rest Of The Health Insurance Providers Stocks | 03/04/2025 |
11 | Health Insurance Providers Stocks Q4 Highlights Molina Healthcare | 03/05/2025 |
12 | Acquisition by Allison Swartz of 22727 shares of Progyny subject to Rule 16b-3 | 03/10/2025 |
13 | Q4 Earnings Outperformers Cigna And The Rest Of The Health Insurance Providers Stocks | 03/13/2025 |
| Begin Period Cash Flow | 97.3 M |
Progyny |
Progyny Relative Risk vs. Return Landscape
If you would invest 1,450 in Progyny on December 18, 2024 and sell it today you would earn a total of 641.00 from holding Progyny or generate 44.21% return on investment over 90 days. Progyny is currently generating 0.664% in daily expected returns and assumes 2.9698% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Progyny, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Progyny Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Progyny's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Progyny, and traders can use it to determine the average amount a Progyny's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2236
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PGNY | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.97 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.66 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average Progyny is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Progyny by adding it to a well-diversified portfolio.
Progyny Fundamentals Growth
Progyny Stock prices reflect investors' perceptions of the future prospects and financial health of Progyny, and Progyny fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Progyny Stock performance.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0618 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 1.53 B | ||||
| Shares Outstanding | 85.41 M | ||||
| Price To Earning | 37.91 X | ||||
| Price To Book | 4.12 X | ||||
| Price To Sales | 1.49 X | ||||
| Revenue | 1.17 B | ||||
| Gross Profit | 253.36 M | ||||
| EBITDA | 67.45 M | ||||
| Net Income | 54.34 M | ||||
| Cash And Equivalents | 122.39 M | ||||
| Cash Per Share | 1.33 X | ||||
| Total Debt | 19.27 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 2.46 X | ||||
| Book Value Per Share | 4.98 X | ||||
| Cash Flow From Operations | 179.1 M | ||||
| Earnings Per Share | 0.57 X | ||||
| Market Capitalization | 1.74 B | ||||
| Total Asset | 607.1 M | ||||
| Retained Earnings | 144.31 M | ||||
| Working Capital | 304.09 M | ||||
About Progyny Performance
Evaluating Progyny's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Progyny has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Progyny has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.15 | 0.16 | |
| Return On Assets | 0.09 | 0.09 | |
| Return On Equity | 0.13 | 0.14 |
Things to note about Progyny performance evaluation
Checking the ongoing alerts about Progyny for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Progyny help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Progyny is unlikely to experience financial distress in the next 2 years | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Q4 Earnings Outperformers Cigna And The Rest Of The Health Insurance Providers Stocks |
- Analyzing Progyny's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Progyny's stock is overvalued or undervalued compared to its peers.
- Examining Progyny's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Progyny's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Progyny's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Progyny's stock. These opinions can provide insight into Progyny's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Progyny Stock Analysis
When running Progyny's price analysis, check to measure Progyny's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Progyny is operating at the current time. Most of Progyny's value examination focuses on studying past and present price action to predict the probability of Progyny's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Progyny's price. Additionally, you may evaluate how the addition of Progyny to your portfolios can decrease your overall portfolio volatility.